Xencor News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.11.22	Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting (Businesswire)
05.10.22	Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting (Businesswire)
09.09.22	Xencor Appoints Nancy Valente, M.D., to Board of Directors (Businesswire)
03.08.22	Xencor Reports Second Quarter 2022 Financial Results (Businesswire)
02.08.22	Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies (PR Newswire)
27.07.22	Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022 (Businesswire)
26.05.22	Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors (Businesswire)
05.05.22	Xencor Reports First Quarter 2022 Financial Results (Businesswire)
28.04.22	Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022 (Businesswire)
08.04.22	Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Businesswire)
08.03.22	Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 (Businesswire)
23.02.22	Xencor Reports Fourth Quarter and Full Year 2021 Financial Results (Businesswire)
16.02.22	Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022 (Businesswire)
02.02.22	Xencor to Present at Upcoming Investor Conferences (Businesswire)
11.01.22	Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones (Businesswire)
06.01.22	Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference (Businesswire)
13.12.21	AstraZeneca Elated On Calquence Data, IMGN's IMGN632 Appears To Be Promising In AML, XRTX On Watch (RTTNews)
12.12.21	Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting (Businesswire)
22.11.21	Zenas BioPharma Buys Worldwide Rights To Obexelimab From Xencor (RTTNews)
12.11.21	Xencor : Early-stage Studies On Vudalimab Suggest PD-1 And CTLA-4 Promise In Prostate Cancer (RTTNews)
27.05.21	Xencor to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
27.05.21	GlaxoSmithKline-Vir COVID-19 Antibody Drug Granted EUA In U.S. (RTTNews)
27.05.21	Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19 (Businesswire)
25.05.21	Xencor, Bristol Myers Ink License Deal To Use Xtend XmAb Technology To Treat COVID-19 - Quick Facts (RTTNews)
25.05.21	Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19 (Businesswire)
12.05.21	Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference (Businesswire)
05.05.21	Xencor Reports First Quarter 2021 Financial Results (Businesswire)
28.04.21	Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases (Businesswire)
28.04.21	Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021 (Businesswire)
10.04.21	Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021 (Businesswire)
11.03.21	Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021 (Businesswire)
03.03.21	Xencor to Present at the Barclays Global Healthcare Conference (Businesswire)
25.02.21	Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics (Businesswire)
23.02.21	Xencor Reports Fourth Quarter and Full Year 2020 Financial Results (Businesswire)
16.02.21	Xencor to Host Fourth Quarter and Full Year 2020 Financial Results Webcast and Conference Call on February 23, 2021 (Businesswire)
04.02.21	Xencor to Present at Upcoming Investor Conferences (Businesswire)
06.01.21	Xencor and MD Anderson Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer (Businesswire)
07.12.20	Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer (Businesswire)
06.12.20	Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting (Businesswire)
12.11.20	Xencor to Present at Upcoming Investor Conferences (Businesswire)
11.11.20	Xencor, MorphoSys And Incyte Ink Collaboration Deal (RTTNews)
11.11.20	Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab (Businesswire)
09.11.20	Xencor Presents Updated Data From the DUET-2 Phase 1 Study of XmAb20717, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting (Businesswire)
09.11.20	Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the SITC Annual Meeting (Businesswire)
05.11.20	Xencor Reports Third Quarter 2020 Financial Results (Businesswire)
04.11.20	Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting (Businesswire)
29.10.20	Xencor to Host Third Quarter 2020 Financial Results Webcast and Conference Call on November 5, 2020 (Businesswire)
14.10.20	Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting (Businesswire)
02.10.20	Xencor Presents Initial Data From the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium (Businesswire)
09.09.20	Xencor to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	534.20	0.60 %	K V
Sonova Hldg	305.30	0.23 %	K V
Alcon	77.70	0.10 %	K V
Roche Hldg G	251.60	0.08 %	K V
Novartis	91.92	-0.01 %	K V
UBS Group	27.53	-0.83 %	K V
CieFinRichemont	121.25	-0.90 %	K V
ABB	49.02	-1.05 %	K V
Sika	225.00	-1.57 %	K V
Logitech Intl	70.46	-2.11 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Xencor Inc

Aktien Top/Flop

Meistgelesene Nachrichten